Ivosidenib—IDH1 inhibitor, commonly mentioned regarding novel CS therapies—showed disease control in IDH1-mutant conventional chondrosarcoma in Phase I (DCR 73.5%, median PFS 5.6 months), but MCS seldom harbours IDH1 mutations and may require alternative therapeutic approaches. The gene discussed is IDH1; the disease is chondrosarcoma.